Androgen deprivation therapy for prostate cancer.
Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.
Singer
Eric A
EA
Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Golijanin
Dragan J
DJ
Miyamoto
Hiroshi
H
Messing
Edward M
EM
D000726:Androgen Antagonists / Q000378:metabolism / Q000627:therapeutic use*; D000728:Androgens / Q000378:metabolism*; D000818:Animals; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000379:methods; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000601:surgery
D000726:Androgen Antagonists; D000728:Androgens